KR20230011912A - 티로신 수용체 키나제 저해제를 제조하기 위한 방법 - Google Patents

티로신 수용체 키나제 저해제를 제조하기 위한 방법 Download PDF

Info

Publication number
KR20230011912A
KR20230011912A KR1020227033977A KR20227033977A KR20230011912A KR 20230011912 A KR20230011912 A KR 20230011912A KR 1020227033977 A KR1020227033977 A KR 1020227033977A KR 20227033977 A KR20227033977 A KR 20227033977A KR 20230011912 A KR20230011912 A KR 20230011912A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
formula
haloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227033977A
Other languages
English (en)
Korean (ko)
Inventor
콜롤 팔
프라산트 데브
하리 프라카쉬
아비나쉬 보루데
Original Assignee
피라미드 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피라미드 바이오사이언스, 인크. filed Critical 피라미드 바이오사이언스, 인크.
Publication of KR20230011912A publication Critical patent/KR20230011912A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227033977A 2020-04-15 2021-04-15 티로신 수용체 키나제 저해제를 제조하기 위한 방법 Pending KR20230011912A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010108P 2020-04-15 2020-04-15
US63/010,108 2020-04-15
PCT/US2021/027538 WO2021211882A1 (en) 2020-04-15 2021-04-15 Methods for preparing tyrosine receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20230011912A true KR20230011912A (ko) 2023-01-25

Family

ID=78083713

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033977A Pending KR20230011912A (ko) 2020-04-15 2021-04-15 티로신 수용체 키나제 저해제를 제조하기 위한 방법

Country Status (12)

Country Link
US (1) US12606565B2 (https=)
EP (1) EP4135700A4 (https=)
JP (1) JP7767301B2 (https=)
KR (1) KR20230011912A (https=)
CN (1) CN115515591B (https=)
AU (1) AU2021255613A1 (https=)
BR (1) BR112022020114A2 (https=)
CA (1) CA3172681A1 (https=)
IL (1) IL296921A (https=)
MX (1) MX2022012437A (https=)
WO (1) WO2021211882A1 (https=)
ZA (1) ZA202209792B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005237SA (en) 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
IL296921A (en) 2020-04-15 2022-12-01 Pyramid Biosciences Inc Methods for making receptor tyrosine kinase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CN101242844A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
WO2014055928A2 (en) * 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
FR3029769A1 (fr) 2014-12-10 2016-06-17 Tornier Sa Kit pour une prothese d'epaule
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
JP6475084B2 (ja) 2015-05-21 2019-02-27 臼井国際産業株式会社 トルクセンサ用シャフトの製造設備およびその製造方法
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
SG11202005237SA (en) * 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
IL296921A (en) 2020-04-15 2022-12-01 Pyramid Biosciences Inc Methods for making receptor tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CA3172681A1 (en) 2021-10-21
WO2021211882A1 (en) 2021-10-21
EP4135700A4 (en) 2024-04-17
US12606565B2 (en) 2026-04-21
US20230242536A1 (en) 2023-08-03
JP2023522841A (ja) 2023-06-01
JP7767301B2 (ja) 2025-11-11
AU2021255613A1 (en) 2022-09-29
CN115515591A (zh) 2022-12-23
EP4135700A1 (en) 2023-02-22
IL296921A (en) 2022-12-01
MX2022012437A (es) 2022-10-27
CN115515591B (zh) 2024-09-27
BR112022020114A2 (pt) 2022-11-29
ZA202209792B (en) 2025-01-29

Similar Documents

Publication Publication Date Title
TWI848925B (zh) 肌旋蛋白激酶抑制劑
TWI828712B (zh) 作為ｔｒｋ抑制劑的雜環化合物
CN110088099A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
CA2932008A1 (en) Fused tricyclic benzimidazoles derivatives as modulators of tnf activity
CN109195968B (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN111343988A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
CA2792339A1 (en) Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
CN114605390B (zh) 具有cdk激酶抑制活性的化合物、其药物组合物和用途
AU2022240765A1 (en) Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
KR20260005337A (ko) 트리시클릭 헤테로시클릭 유도체 및 이의 조성물과 응용
KR20230011912A (ko) 티로신 수용체 키나제 저해제를 제조하기 위한 방법
EA036289B1 (ru) Конденсированные трициклические имидазопиразины в качестве ингибиторов активности tnf
TW202502751A (zh) Cbl-b抑制劑
CA3018907A1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN120092010A (zh) 多环类聚（adp核糖）聚合酶选择性抑制剂
EP3227292A1 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
KR20250047747A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
WO2026019442A1 (en) Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors
WO2026051746A1 (zh) 化合物、包含其的药物组合物及其制备方法和用途
HK40046916B (zh) 作为激酶抑制剂的酰胺化合物、组合物和治疗方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000